CTLA4 and classic Hodgkin lymphoma: The mAbs against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have shown substantial therapeutic activity in heavily treated classical Hodgkin lymphoma (cHL) and encouraging results in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with overall response rates (ORR) of 87% and 36% respectively.4-8